|Articles|June 15, 2003

BioPharm International

  • BioPharm International-06-01-2003
  • Volume 16
  • Issue 6

BioTrends: M&A Malaise

by Desiree de Myer, BioPharm International Despite market conditions favorable to merger and acquisition activity, a frenzy of consolidations still hasn't taken place.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 22 years ago

Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth

over 22 years ago

Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement

over 22 years ago

Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection

over 22 years ago

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

over 22 years ago

The Project Management Institute's Pharmaceutical Specific Interest Group 2002 Benchmark Survey Results: Project Managers and Project Management in the Biotech Industry

over 22 years ago

Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development

over 22 years ago

Inside Washington: Reshaping Biotech Drug Development

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!